Search results
Showing 1 to 11 of 11 results for teriparatide
Evidence-based recommendations on raloxifene and teriparatide for preventing osteoporotic fragility fractures in postmenopausal women who have osteoporosis.
View recommendations for TA161Show all sections
Abaloparatide for treating osteoporosis after menopause (TA991)
Evidence-based recommendations on abaloparatide (Eladynos) for treating osteoporosis after menopause in women, trans men and non-binary people with a very high risk of fracture.
Palopegteriparatide for treating chronic hypoparathyroidism [ID6380]
In development [GID-TA11454] Expected publication date: 16 July 2025
Denosumab for the prevention of osteoporotic fractures in postmenopausal women (TA204)
Evidence-based recommendations on denosumab (Prolia) for preventing osteoporotic fragility fractures in postmenopausal women.
Evidence-based recommendations on romosozumab (EVENITY) for severe osteoporosis in people after menopause who are at high risk of fracture.
This quality standard covers managing osteoporosis in adults (aged 18 and over), including assessing risk and preventing fragility fractures. It describes high-quality care in priority areas for improvement.
View quality statements for QS149Show all sections
This guideline covers managing hip fracture in adults. It aims to improve care from the time people aged 18 and over are admitted to hospital through to when they return to the community. Recommendations emphasise the importance of early surgery and coordinating care through a multidisciplinary Hip Fracture Programme to help people recover faster and regain their mobility.
Source guidance details Comes from guidance Raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures...
Discontinued [GID-TA10072]
Evidence-based recommendations on raloxifene for the primary prevention of osteoporotic fragility fractures in postmenopausal women.
View recommendations for TA160Show all sections
14,000 women at risk of fractures after the menopause to benefit from bone disease drug
Over 14,000 people to benefit after NICE published final guidance recommending abaloparatide as an option for treating osteoporosis after menopause, if there is a very high risk of fracture.